HealthQuill Drug development
Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs to be jointly developed, according to a statement.
Drugs Health Medical

Novo Nordisk, Valo expand pact to include obesity, diabetic drugs

Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.

Read More
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a form of lung cancer improved patients’ chances of extending survival without the disease progressing.
Drugs Health Pharma

Daiichi Sankyo-Merck’s trial lung cancer drug meets primary goal

Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a.

Read More
https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/
Drugs Health Pharma

Daiichi Sankyo to pay Merck $170 million for cancer test drug rights

Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.

Read More
Cardiometabolic diseases are a group of common but often preventable conditions including heart attack, stroke, diabetes, insulin resistance and non-alcoholic fatty liver disease.
Drugs Health Pharma

Novo Nordisk, Valo Health sign $2.7 billion pact for drug discovery

HQ Team September 25, 2023: Novo Nordisk and Valo Health, Inc., have signed a $2.7 billion pact to discover and develop novel treatments.

Read More
US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from eventual revenue loss as patents on its cancer immunotherapy Keytruda expires by the end of the decade.
Drugs Pharma

Merck to acquire Prometheus for $10.8 billion to step up immunology presence

HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.

Read More
BioNTech, a German immunotherapy company, announced a strategic pact with OncoC4, a private firm, to develop and commercialise a drug to treat solid tumours.
Drugs Medical Pharma

BioNTech, OncoC4 in pact to develop drug for solid tumours

BioNTech, a German immunotherapy company, announced a strategic pact with OncoC4, a private firm, to develop and commercialise a drug to treat solid tumours.

Read More